Worsening of unrecognized tumor-induced osteomalacia with inadvertent use of recombinant human parathyroid hormone.
Introduction Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by refractory hypophosphatemia mediated by fibroblast growth factor 23 (FGF23) produced by small, mesenchymal tumors. Herein, we report a hitherto unrecognized case of TIO whose hypophosphatemic symptoms got suddenly worsened following inadvertent use of teriparatide. Case Presentation A 45-years-old gentleman presented with lower limb proximal myopathy for the past 1½ year. Six months back he suffered bilateral femoral neck fractures following a trivial trauma for which he underwent bilateral total hip replacement. He was started on teriparatide to promote fracture healing without prior assessment of serum phosphate levels. After 1 month, his myopathy rapidly worsened and within 6 months, he became completely bed-bound. Examination revealed reduced lower limb proximal muscle power with intact deep tendon reflexes. Biochemical investigations showed hypophosphatemia, normocalcemia, elevated alkaline phosphatase and low tubular reabsorption of phosphate corrected for glomerular filtration rate (TmP/GFR). Serum FGF23 was elevated with inappropriately low 1, 25-dihydroxy vitamin D. 68Ga-DOTATATE PET-CT showed a small tracer-avid soft tissue lesion in the left thigh. The lesion was excised and histopathology showed phosphaturic mesenchymal tumor. Phosphate levels rose and FGF23 levels fell post-operatively. At 3 months follow-up, he is able to stand and walk by himself. His serum phosphate has normalized. Conclusion Hypophosphatemia with teriparatide use is an oddity. Unexplained hypophosphatemia in a patient on teriparatide should make the physician think of hypophosphatemic osteomalacia. Serum phosphate levels should be estimated prior to teriparatide use and its use refrained in patients with unexplained hypophosphatemia.